GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults

benzinga.com/news/fda/25/07/46423319/gsk-seeks-fda-nod-to-broaden-rsv-vaccine-for-younger-at-risk-adults

On Monday, the U.S. Food and Drug Administration (FDA) agreed to review GSK plc’s (NYSE:GSK) application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk.
GSK's RSV vaccine is approved in the U.S. to…

This story appeared on benzinga.com, 2025-07-15 16:06:38.
The Entire Business World on a Single Page. Free to Use →